A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Eligible age
50+ yrs
Accepts
All genders
Locations
25 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Sponsor: EyeBiotech Ltd.
Where it's recruiting
Gilbert
Encino · Mountain View · Santa Ana
Colorado Springs · Denver · Pueblo
Danbury · Manchester · Waterford
Fort Myers · Orlando · Sarasota · Winter Haven
Joliet · Lemont
West Des Moines
Lenexa
Louisville
Portland
Hagerstown
Springfield
Source: ClinicalTrials.gov · NCT07496567 · last updated 2026-08-06